Cabozantinib monotherapy (metastatic non-MIBG-avid pheochromocytoma/paraganglioma, alternative to sunitinib)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-CABOZANTINIB`

ID	`REG-CABOZANTINIB-PHEO`
Type	Regimen
Status	reviewed 2026-07-11 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-NCCN-NET-2025`

Notes

Cabozantinib is an NCCN-listed alternative to sunitinib for metastatic non-MIBG-avid PPGL, but rests on smaller single-arm / retrospective evidence rather than a randomized trial (unlike sunitinib's FIRSTMAPPP RCT -- see REG-SUNITINIB-PHEO). The drafting agent could not confirm a specific cabozantinib-in-PPGL trial name/citation with enough confidence to author a dedicated Source stub, so this regimen is cited only via the existing SRC-NCCN-NET-2025 guideline rather than a fabricated trial reference. Dose (60 mg daily) reuses the standard cabozantinib monotherapy dose already established in REG-CABOZANTINIB- RCC / REG-CABOZANTINIB-MTC-1L in this KB, not an invented number. STUB pending clinical co-lead signoff (CHARTER §6.1, dev-mode-exempted).

Used By

Indication

IND-PHEO-METASTATIC-1L-CABOZANTINIB - IND-PHEO-METASTATIC-1L-CABOZANTINIB

Regimen

REG-SUNITINIB-PHEO - Sunitinib monotherapy (metastatic non-MIBG-avid pheochromocytoma/paraganglioma; FIRSTMAPP...